Moderately bullish activity in ImmunityBio (IBRX), with shares down 50c near $8.18. Options volume relatively light with 26k contracts traded and calls leading puts for a put/call ratio of 0.25, compared to a typical level near 0.25. Implied volatility (IV30) is higher by 1.5 points near 119.66,in the top quartile of the past year, suggesting an expected daily move of $0.62. Put-call skew flattened, suggesting a modestly bullish tone.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IBRX:
- ImmunityBio resubmits sBLA to FDA for Anktiva plus BCG
- Mixed options sentiment in ImmunityBio with shares down 10.25%
- ImmunityBio price target raised to $12 from $7 at Piper Sandler
- ImmunityBio: Advancing ANKTIVA Into a Global, Multi-Indication Immunotherapy Platform Supporting a Buy Rating and $15 Target
- IBRX Earnings this Week: How Will it Perform?